Autolus Therapeutics (NASDAQ:AUTL) Trading Down 5.2%

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price fell 5.2% during trading on Tuesday . The stock traded as low as $4.02 and last traded at $4.03. 125,432 shares changed hands during trading, a decline of 92% from the average session volume of 1,557,722 shares. The stock had previously closed at $4.25.

Analysts Set New Price Targets

Several brokerages have recently commented on AUTL. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research note on Monday, June 3rd. Needham & Company LLC reissued a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. Finally, Truist Financial boosted their price target on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.70.

Autolus Therapeutics Trading Down 8.2 %

The firm has a market capitalization of $1.04 billion, a PE ratio of -3.25 and a beta of 2.11. The firm has a 50-day moving average of $4.09 and a two-hundred day moving average of $4.94.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The company had revenue of $10.09 million during the quarter, compared to analyst estimates of $50.00 million. During the same quarter in the prior year, the business earned ($0.23) earnings per share. Equities research analysts expect that Autolus Therapeutics plc will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bayesian Capital Management LP acquired a new stake in Autolus Therapeutics in the 1st quarter valued at $100,000. B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics in the 1st quarter valued at $108,000. SG Americas Securities LLC acquired a new stake in Autolus Therapeutics in the 1st quarter valued at $127,000. EntryPoint Capital LLC increased its holdings in Autolus Therapeutics by 113.6% in the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after purchasing an additional 11,456 shares in the last quarter. Finally, EWA LLC grew its stake in shares of Autolus Therapeutics by 40.2% during the fourth quarter. EWA LLC now owns 25,678 shares of the company’s stock valued at $155,000 after acquiring an additional 7,361 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.